Company intelligence / Profile preview

Kamada Law

Ownership: Private
Employees: ~400
Development stage: Other

Overview

Kamada has six FDA-approved commercial plasma-derived products marketed globally for rare diseases and serious conditions. Its lead investigational program is an inhaled AAT therapy in pivotal Phase 3 trials for AAT deficiency. The company also distributes biosimilars in Israel and continues to expand its portfolio through acquisitions.

Therapeutic areas: HematologyRare DiseasesInfectious Diseases
Modalities: BiologicPlasma-derived proteinRecombinant protein
Industry: Biotech

Partnerships

Takeda PharmaceuticalsKedrion S.p.A.Baxter InternationalSaol Therapeutics (asset acquisition)Alvotech (biosimilars distribution)undisclosed international pharma partners

Beyond the preview

Go deeper on Kamada Law.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kamada Law.

Explore the full profile